> top > docs > PubMed:15691303 > annotations

PubMed:15691303 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 321-349 gene:1557 denotes S-mephenytoin 4'-hydroxylase
T1 243-262 disease:C0374997 denotes Helicobacter pylori
T2 351-358 gene:1557 denotes CYP2C19
T3 243-262 disease:C0374997 denotes Helicobacter pylori
R1 T0 T1 associated_with S-mephenytoin 4'-hydroxylase,Helicobacter pylori
R2 T2 T3 associated_with CYP2C19,Helicobacter pylori

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
15691303-0#112#119#gene1557 112-119 gene1557 denotes CYP2C19
15691303-0#69#88#diseaseC0374997 69-88 diseaseC0374997 denotes Helicobacter pylori
112#119#gene155769#88#diseaseC0374997 15691303-0#112#119#gene1557 15691303-0#69#88#diseaseC0374997 associated_with CYP2C19,Helicobacter pylori

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 137-360 OBJECTIVE denotes To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S-mephenytoin 4'-hydroxylase (CYP2C19).
T2 370-779 METHODS denotes Two hundred H. pylori-infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or esomeprazole 40 mg twice daily for 1 week. Six weeks later, the success of H. pylori eradication was defined. The genotyping of CYP2C19 in each patient was defined as homologous, heterologous extensive metabolizer or poor metabolizer.
T3 789-1311 RESULTS denotes The age, gender, drug compliance and proportion of CYP2C19 genotypes were similar between the two groups. The H. pylori eradication rates were also similar between the omeprazole group and the esomeprazole group (intention-to-treat analysis: 79% vs. 86%, P > 0.05; per-protocol analysis: 85% vs. 94%, P > 0.05). For patients classified as homologous extensive metabolizers, the per-protocol H. pylori eradication rate was significantly higher in the esomeprazole group than in the omeprazole group (93% vs. 76%, P < 0.05).
T4 1324-1508 CONCLUSIONS denotes Esomeprazole 40 mg twice daily for triple therapy may improve the H. pylori eradication compared to omeprazole-based therapy, but only for homologous extensive metabolizers of CYP2C19.